A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone. Studies suggest that dose-dense temozolomide schedules and addition of cytostatic age...

Full description

Bibliographic Details
Main Authors: Gilbert, Mark R., Gonzalez, Javier, Hunter, Kathy, Hess, Kenneth, Giglio, Pierre, Chang, Eric, Puduvalli, Vinay, Groves, Morris D., Colman, Howard, Conrad, Charles, Levin, Victor, Woo, Shaio, Mahajan, Anita, de Groot, John, Yung, W.K. Alfred
Format: Online
Language:English
Published: Oxford University Press 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098026/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098026/

Similar Items